Indiana Alzheimer's Disease Research Center

印第安纳阿尔茨海默病研究中心

• 批准号: 10475170
• 负责人: ANDREW J SAYKIN
• 金额: $ 304.73万
• 依托单位: INDIANA UNIV-PURDUE UNIV AT INDIANAPOLIS
• 依托单位国家: 美国
• 财政年份: 2021
• 资助国家: 美国
• 起止时间: 2021-09-01 至 2026-06-30
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10475170
• 关键词: Address; Aging; Alzheimer' s Disease; Alzheimer' s disease model; Alzheimer' s disease related dementia; Animal Model; Awareness; Biological; Biological Markers; Biological Models; Brain; Caregivers; Clinical; Clinical Trials; Cognition; Collaborations; Communities; Complex; DNA sequencing; Data; Data Science; Data Scientist; Dementia; Development; Diagnosis; Discipline; Disease; Early Diagnosis; Early Intervention; Environment; Environmental Risk Factor; Etiology; Family; Family member; Fostering; Functional disorder; Genetic; Goals; Growth; Healthcare; Heterogeneity; Image; Impaired cognition; Indiana; Individual; Industry; Informatics; Inherited; Interdisciplinary Study; International; Intervention; Leadership; Machine Learning; Maps; Methodology; Methods; Molecular; Molecular Genetics; Nature; Nerve Degeneration; Participant; Pathogenesis; Pathway interactions; Patients; Persons; Pharmacology; Phase; Phenotype; Population Heterogeneity; Positioning Attribute; Positron-Emission Tomography; Prevalence; Prevention; Process; Proteomics; Research; Research Infrastructure; Research Personnel; Resource Development; Resources; Risk; Role; Science; Scientific Advances and Accomplishments; Scientist; Staging; Symptoms; Systems Biology; Targeted Research; Therapeutic; Thinking; Time; Training and Education; Translational Research; Translations; Underrepresented Populations; Universities; academic program; advanced analytics; base; biological heterogeneity; brain health; caregiver interventions; clinical phenotype; cognitive testing; cohort; collaborative approach; cost effective; disparity reduction; dosage; early detection biomarkers; effective therapy; imaging biomarker; improved; induced pluripotent stem cell; innovation; lifestyle factors; medical schools; medical specialties; member; metabolomics; method development; mild cognitive impairment; multimodal neuroimaging; multiple omics; neuropathology; new therapeutic target; non-drug; novel; novel diagnostics; novel strategies; pre-clinical; precision medicine; prevent; programs; racial and ethnic; ranpirnase; recruit; socioeconomic disparity; socioeconomic diversity; stem; success; successful intervention; tau Proteins; therapeutic development; tool development; training opportunity; transcriptome sequencing; translational scientist

Project Summary – IADRC Overall The Indiana Alzheimer’s Disease Research Center (IADRC) was established in 1991 to bring investigators and institutional resources at the Indiana University School of Medicine (IUSM) together to address the fundamental causes and treatment of Alzheimer’s disease (AD) and related dementias (ADRD). Despite many important gains, the need for targeted research is greater than ever, with an estimated 5.8 million people in the U.S. suffering from AD/ADRD. Unfortunately, we do not yet know how to prevent AD or have an approved disease modifying intervention. Both are critical to stem the growth in dementia prevalence. The overarching goal of the IADRC going forward is to support the goal of the NAPA to prevent and effectively treat AD by 2025, through innovative research on etiology, early detection, and therapeutics. Biomarker studies indicate that processes leading to AD begin at least 20 years prior to dementia, suggesting that successful interventions must be implemented early. This presents a potential opportunity for early intervention, but the field is challenged by critical barriers decreasing the prospects of timely success. The IADRC has identified the barriers as: a) The current understanding of etiology and pathophysiology is fragmented and incomplete; b) Sensitive, specific, and cost-effective methods for early detection are not available; c) Therapeutic development is hampered by the heterogeneity and complexity of ADRD; d) Shortage of data and translational scientists; and, e) Inadequate diversity at all levels. The IADRC specific aims entail innovation to overcome these barriers and accelerate research toward prevention and effective treatment: 1) Support, enhance, and expand innovative research on ADRD targeting causes, diagnosis, treatment, and prevention; 2) Provide critical research resources and infrastructure to support existing studies and enable new innovative research, utilizing a well-characterized longitudinal clinical cohort, with prioritization of diverse populations including underrepresented groups (URG) and those in preclinical and early symptomatic phases, including subjective cognitive decline and mild cognitive impairment, which will help to advance the identification of easily accessible biomarkers for early detection; 3) Identify and prioritize novel therapeutic targets from high-throughput approaches with rapid translation to proof- of-concept studies using genetic and other enrichment strategies for better biological targeting and reduction of phenotypic and biological heterogeneity for more efficient and cost-effective clinical trials; 4) Increase the number of investigators with deep expertise in advanced data sciences to bridge cellular/molecular processes of neurodegeneration and clinical phenotypes, as well as clinical and translational researchers who can move therapeutic approaches from model systems to clinical trials; 5) Provide educational and training opportunities related to dementia for a broad array of learners, with special emphasis on increasing participation from URG in ADRD related research and healthcare specialties. The IADRC is well-positioned to help achieve the NIA/NAPA goals through sustained and impactful contributions towards prevention and treatment of AD/ADRD.

项目摘要- IADRC总体 印第安纳州阿尔茨海默病研究中心（IADRC）成立于1991年， 印第安纳州大学医学院（IUSM）的机构资源，共同解决基本的 阿尔茨海默病（AD）和相关痴呆（ADRD）的病因和治疗。尽管许多重要的 随着研究成果的增加，对有针对性的研究的需求比以往任何时候都要大，据估计，美国有580万人。 患有AD/ADRD。不幸的是，我们还不知道如何预防AD或有一个批准的疾病 修改干预。这两者对于阻止痴呆症患病率的增长至关重要。的首要目标 IADRC的下一步工作是支持国家适应行动方案到2025年预防和有效治疗AD的目标， 病原学、早期发现和治疗的创新研究。生物标志物研究表明， 导致AD至少在痴呆症前20年开始，这表明成功的干预措施必须是 早日实施。这为早期干预提供了一个潜在的机会，但该领域面临着以下挑战： 降低及时成功前景的关键障碍。IADRC将障碍确定为： 目前对病因学和病理生理学的理解是零散和不完整的; B）敏感的，特异的， 没有成本效益高的早期检测方法; c）治疗发展受到 ADRD的异质性和复杂性; d）缺乏数据和翻译科学家;以及，e）不充分 各级多样性。IADRC的具体目标需要创新来克服这些障碍， 预防和有效治疗的研究：1）支持，加强和扩大创新研究， ADRD针对病因、诊断、治疗和预防; 2）提供关键的研究资源， 基础设施，以支持现有的研究，使新的创新研究，利用一个良好的特点， 纵向临床队列，优先考虑不同人群，包括代表性不足的人群（URG） 以及处于临床前和早期症状阶段的患者，包括主观认知下降和轻度认知功能障碍。 损伤，这将有助于促进识别易于获得的生物标志物，以便早期检测; 3） 从高通量方法中识别和优先考虑新型治疗靶点，并快速转化为证据- 使用基因和其他富集策略进行概念研究，以更好地实现生物靶向， 表型和生物学异质性，以进行更有效和更具成本效益的临床试验; 4）增加 研究人员在先进的数据科学方面具有深厚的专业知识，以桥接细胞/分子过程， 神经变性和临床表型，以及临床和翻译研究人员谁可以移动 从模型系统到临床试验的治疗方法; 5）提供教育和培训机会 与痴呆症有关的广泛学习者，特别强调提高URG参与 ADRD相关研究和医疗保健专业。机构间发展研究中心完全有能力帮助实现国家执行机构/国家适应行动方案 通过对AD/ADRD的预防和治疗做出持续和有影响力的贡献来实现目标。